Pharmafile Logo
Pharmafocus logo
Advanced Search

Seretide

Showing 12 posts of 12 posts found.

GSK image

GSK double complaint ruled out by PMCPA

January 16, 2015
Medical Communications, Sales and Marketing ABPI, COPD, GSK, PMCPA, Relvar, Seretide

Complaints questioning the promotion of two of GlaxoSmithKline’s chronic obstructive pulmonary disease (COPD) drugs have been ruled out by a …

News
Novartis image

Novartis seeks FDA approval for lung drugs

January 8, 2015
Sales and Marketing Advair, FDA, GSK, NVA237, Novartis, QVA149, Seretide, asthma, lung copd

Novartis has submitted two new lung treatments for FDA approval after ‘robust’ Phase III trial results. If approved, QVA149 and …

News
GSK image

GSK sees profit fall

May 1, 2014
Sales and Marketing Advair, China, GSK, Novartis, Q1, Seretide, Witty

GlaxoSmithKline has seen revenue and profit plummet in the first quarter of 2014. The UK-based company saw turnover fall 13% …

News
gsk image

GSK sales up – impact of China allegations to follow

July 24, 2013
Sales and Marketing GSK, Q2, Seretide, Seroxat, Witty, bribery, transparency

GlaxoSmithKline has reported a modest rise in sales but the fallout from China’s bribery probe dominates the firm’s release of …

News
Eklira image

Almirall’s COPD drug launched in Europe

September 20, 2012
Sales and Marketing Advair, Almirall, Eklira, Genuair, Seretide, Spiriva

Almirall has launched COPD treatment Eklira in Denmark following approval from the European Commission. Phase III trials demonstrated that Eklira …

News

GSK falters in Q2 as austerity measures bite

July 25, 2012
Sales and Marketing Benylsta, GSK, Q2, Seretide, Witty

GlaxoSmithKline posted a loss in its second quarter results, as pressure in mature markets continues to affect the firm. Pharmaceutical …

News
GSK picture

GSK posts strong underlying sales growth

February 8, 2012
Research and Development, Sales and Marketing Avodart, GSK, R&D, Seretide, Witty, rotarix

GlaxoSmithKline has posted strong underlying growth for 2011, but warns of a tough year ahead.  The UK firm saw 4% …

News

Underwhelming results for GSK’s Relovair

January 10, 2012
Research and Development, Sales and Marketing Advair, COPD, GSK, Relovair, Seretide, asthma

GlaxoSmithKline says it is on track to file its respiratory drug Relovair in Europe and the US despite mixed results …

News

GSK cleared of unethical practices by PMCPA

October 22, 2010
Medical Communications ABPI, ABPI Code of Practice, Avamys, GSK, GlaxoSmithKline, PMCPA, Rupafin, Seretide

GlaxoSmithKline has been found guilty of two transgressions of the ABPI Code of Practice in a case centring on the …

News

German patent setback for GlaxoSmithKline’s Seretide

May 21, 2010
Sales and Marketing GSK, Germany, Seretide

A Munich court has ruled GlaxoSmithKline’s combination patent for its asthma and COPD treatment Seretide is not valid. The Federal …

News

GSK’s Relovair moves into phase III

March 19, 2010
Research and Development GlaxoSmithKline, Relovair, Seretide, Theravance, respiratory

GlaxoSmithKline has started phase III asthma trials of Relovair, the respiratory treatment it is developing with San Francisco biopharma firm …

News

GSK begins phase III COPD trials

October 28, 2009
Research and Development, Sales and Marketing COPD, GSK, GlaxoSmithKline, Seretide, Theravance, resp, respiratory

GlaxoSmithKline and San Francisco biopharma firm Theravance have begun a phase III trial to develop a new treatment for chronic …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025